SEC Form 4 · accession 0000886163-15-000070
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew W Foehr
Officer — President and COO
Period of report
Jun 22, 2015
Accepted (ET)
Jun 24, 2015 · 6:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 22, 2015 | M | 23,046 | $9.97 | A | 91,174 | D | |
| Common StockF1,F2 | Jun 22, 2015 | S | 4,546 | $95.77 | D | 86,628 | D | |
| Common StockF1,F3 | Jun 22, 2015 | S | 15,145 | $96.43 | D | 71,483 | D | |
| Common StockF1,F4 | Jun 22, 2015 | S | 3,355 | $97.47 | D | 68,128 | D | |
| Common Stock | Jun 22, 2015 | M | 2,000 | $9.97 | A | 70,128 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F5 | $9.97 | Jun 22, 2015 | M | 23,046 | D | — | Apr 18, 2021 | Common Stock | 23,046 | 109,010 | D |
| Employee Stock Option (right to buy)F5 | $9.97 | Jun 22, 2015 | M | 2,000 | D | — | Apr 18, 2021 | Common Stock | 2,000 | 107,010 | D |
Explanation of responses
- F1The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 20, 2015, in accordance with Rule 10b5-1.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.99, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.97, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.00 to $97.89, inclusive.
- F5Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11.